Oral Semaglutide Improves ASCVD Risk Factors in High-Risk T2D Patients: Study
A recent post hoc analysis published the Journal of the American Medical Association revealed oral semaglutide to show early and sustained improvements in multiple atherosclerotic cardiovascular disease (ASCVD) risk factors…